HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $105 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on SpringWorks Therapeutics (NASDAQ:SWTX) and maintained a $105 price target.
June 06, 2023 | 10:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on SpringWorks Therapeutics (SWTX) and maintained a $105 price target.
The reiteration of the Buy rating and maintenance of the $105 price target by HC Wainwright & Co. analyst Robert Burns indicates a positive outlook for SpringWorks Therapeutics (SWTX) in the short term. This news is important for investors as it reaffirms the analyst's confidence in the company's potential growth and stock performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100